SMARCB1 is altered in 1.15% of malignant solid tumor patients with SMARCB1 Loss present in 0.22% of all malignant solid tumor patients [4].

SMARCB1 Loss is an inclusion criterion in 18 clinical trials for malignant solid tumor, of which 15 are open and 3 are closed. Of the trials that contain SMARCB1 Loss and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 4 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [5].

SMARCB1 is altered in 0.57% of prostate adenocarcinoma patients with SMARCB1 Loss present in 0.19% of all prostate adenocarcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain SMARCB1 Loss and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [5].

SMARCB1 is altered in 55.17% of rhabdoid tumor patients with SMARCB1 Loss present in 53.33% of all rhabdoid tumor patients [4].

SMARCB1 Loss is an inclusion criterion in 6 clinical trials for rhabdoid tumor, of which 5 are open and 1 is closed. Of the trials that contain SMARCB1 Loss and rhabdoid tumor as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (4 open) [5].

SMARCB1 is altered in 0.56% of prostate carcinoma patients with SMARCB1 Loss present in 0.19% of all prostate carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain SMARCB1 Loss and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].

SMARCB1 is altered in 0.8% of breast carcinoma patients with SMARCB1 Loss present in 0.07% of all breast carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain SMARCB1 Loss and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 2 (0 open) [5].

SMARCB1 is altered in 1.1% of ovarian carcinoma patients with SMARCB1 Loss present in 0.87% of all ovarian carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain SMARCB1 Loss and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [5].

SMARCB1 is altered in 1.62% of non-hodgkin lymphoma patients with SMARCB1 Loss present in 0.14% of all non-hodgkin lymphoma patients [4].

SMARCB1 Loss is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain SMARCB1 Loss and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].

SMARCB1 is altered in 36.17% of epithelioid sarcoma patients with SMARCB1 Loss present in 33.33% of all epithelioid sarcoma patients [4].

SMARCB1 Loss is an inclusion criterion in 3 clinical trials for epithelioid sarcoma, of which 2 are open and 1 is closed. Of the trials that contain SMARCB1 Loss and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

SMARCB1 is altered in 0.79% of synovial sarcoma patients with SMARCB1 Loss present in 0.85% of all synovial sarcoma patients [4].

SMARCB1 Loss is an inclusion criterion in 3 clinical trials for synovial sarcoma, of which 2 are open and 1 is closed. Of the trials that contain SMARCB1 Loss and synovial sarcoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

SMARCB1 is altered in 0.62% of cervical carcinoma patients with SMARCB1 Loss present in 0.3% of all cervical carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain SMARCB1 Loss and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 1.45% of colorectal carcinoma patients with SMARCB1 Loss present in 0.02% of all colorectal carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain SMARCB1 Loss and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [5].

SMARCB1 Loss is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain SMARCB1 Loss and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 50.0% of atypical teratoid/rhabdoid tumor patients with SMARCB1 Loss present in 54.55% of all atypical teratoid/rhabdoid tumor patients [4].

SMARCB1 Loss is an inclusion criterion in 2 clinical trials for atypical teratoid/rhabdoid tumor, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 Loss and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

SMARCB1 is altered in 71.43% of rhabdoid tumor of the kidney patients with SMARCB1 Loss present in 50.0% of all rhabdoid tumor of the kidney patients [4].

SMARCB1 Loss is an inclusion criterion in 2 clinical trials for rhabdoid tumor of the kidney, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 Loss and rhabdoid tumor of the kidney as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

SMARCB1 is altered in 11.76% of kidney medullary carcinoma patients with SMARCB1 Loss present in 21.43% of all kidney medullary carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 2 clinical trials for kidney medullary carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 Loss and kidney medullary carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

SMARCB1 is altered in 1.65% of soft tissue sarcoma patients with SMARCB1 Loss present in 1.13% of all soft tissue sarcoma patients [4].

SMARCB1 Loss is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 0 are open and 2 are closed. Of the trials that contain SMARCB1 Loss and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [5].

SMARCB1 is altered in 1.32% of malignant central nervous system neoplasm patients with SMARCB1 Loss present in 0.39% of all malignant central nervous system neoplasm patients [4].

SMARCB1 Loss is an inclusion criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 Loss and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

SMARCB1 is altered in 0.86% of adenocarcinoma of the gastroesophageal junction patients with SMARCB1 Loss present in 0.33% of all adenocarcinoma of the gastroesophageal junction patients [4].

SMARCB1 Loss is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 Loss and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 1.85% of endometrial carcinoma patients with SMARCB1 Loss present in 0.1% of all endometrial carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 Loss and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 0.74% of head and neck squamous cell carcinoma patients with SMARCB1 Loss present in 0.1% of all head and neck squamous cell carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCB1 Loss and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 2.06% of urothelial carcinoma patients with SMARCB1 Loss present in 0.06% of all urothelial carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 Loss and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

SMARCB1 is altered in 0.83% of non-small cell lung carcinoma patients with SMARCB1 Loss present in 0.02% of all non-small cell lung carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCB1 Loss and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

SMARCB1 is altered in 1.93% of bladder carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCB1 Loss and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

SMARCB1 Loss is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 Loss and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

SMARCB1 is altered in 6.15% of chordoma patients with SMARCB1 Loss present in 3.64% of all chordoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and chordoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SMARCB1 is altered in 1.2% of retinoblastoma patients with SMARCB1 Loss present in 1.41% of all retinoblastoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and retinoblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 is altered in 1.24% of high grade ovarian serous adenocarcinoma patients with SMARCB1 Loss present in 1.11% of all high grade ovarian serous adenocarcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 Loss and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

SMARCB1 is altered in 1.12% of malignant ovarian epithelial tumor patients with SMARCB1 Loss present in 0.77% of all malignant ovarian epithelial tumor patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 2.62% of mature T-cell and NK-cell non-hodgkin lymphoma patients with SMARCB1 Loss present in 0.61% of all mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 is altered in 0.66% of gastrointestinal stromal tumor patients with SMARCB1 Loss present in 0.59% of all gastrointestinal stromal tumor patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 1.12% of esophageal carcinoma patients with SMARCB1 Loss present in 0.25% of all esophageal carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 0.38% of small cell lung carcinoma patients with SMARCB1 Loss present in 0.23% of all small cell lung carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 1.54% of lymphoma patients with SMARCB1 Loss present in 0.21% of all lymphoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 is altered in 0.79% of malignant esophagogastric neoplasm patients with SMARCB1 Loss present in 0.15% of all malignant esophagogastric neoplasm patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 2.04% of endometrial endometrioid adenocarcinoma patients with SMARCB1 Loss present in 0.09% of all endometrial endometrioid adenocarcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 Loss and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SMARCB1 is altered in 0.28% of pancreatic adenocarcinoma patients with SMARCB1 Loss present in 0.08% of all pancreatic adenocarcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SMARCB1 is altered in 0.27% of pancreatic carcinoma patients with SMARCB1 Loss present in 0.08% of all pancreatic carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 is altered in 1.45% of malignant intestinal neoplasm patients with SMARCB1 Loss present in 0.02% of all malignant intestinal neoplasm patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 is altered in 0.13% of acute myeloid leukemia patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 is altered in 1.68% of ampulla of vater carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 1.03% of anal carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 Loss and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

SMARCB1 is altered in 1.99% of bladder urothelial carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SMARCB1 is altered in 0.78% of cholangiocarcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for dedifferentiated chordoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and dedifferentiated chordoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SMARCB1 is altered in 1.51% of diffuse large B-cell lymphoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for extrarenal rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and extrarenal rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 is altered in 0.45% of gastric carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and hepatoblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

SMARCB1 is altered in 0.45% of malignant gastric neoplasm patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 1.02% of malignant ovarian clear cell tumor patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 Loss and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

SMARCB1 is altered in 2.37% of malignant ovarian endometrioid tumor patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 Loss and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

SMARCB1 is altered in 1.48% of malignant small intestinal neoplasm patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

SMARCB1 is altered in 2.79% of mantle cell lymphoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

SMARCB1 is altered in 3.57% of penile carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 Loss and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

SMARCB1 is altered in 1.74% of renal cell carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SMARCB1 is altered in 0.61% of sarcomatoid carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 Loss and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SMARCB1 is altered in 7.21% of unclassified renal cell carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for unclassified renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 Loss and unclassified renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SMARCB1 is altered in 14.29% of vaginal carcinoma patients [4].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 Loss and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

SMARCB1 Loss is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCB1 Loss and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].